Upgrade to SI Premium - Free Trial

TD Cowen Reiterates Buy Rating on AstraZeneca (AZN) Amid Potential 'Multi-Billion $ Opportunity'

March 30, 2026 8:36 AM
TD Cowen analyst Steve Scala reiterated a Buy rating and $240.00 price target on AstraZeneca (NASDAQ: AZN).The analyst commented: "Positive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments